To clarify the role of neuropeptide Y (NPY) in the regulation of the reproductive axis, these experiments evaluated the extent to which reproductive hormone secretions may be compromised in the absence of NPY expression. In NPY knockout (NPY-KO) and wild-type (WT) mice, hormone secretions were analyzed under conditions of basal release, following ovariectomy (OVX), in proestrus, after estrogen treatments which induce gonadotropin surges and after injection of gonadotropin-releasing hormone (GnRH). Radioimmunoassays of serum from metestrous females revealed that basal luteinizing hormone (LH), follicular-stimulating hormone (FSH), estrogen and progesterone levels, as well as hypothalamic GnRH tissue concentrations, were not different between the two genotypes. The LH and FSH levels and GnRH tissue concentrations were likewise similar in WT and NPY-KO mice 5 and 10 days following OVX. Significant differences in LH levels were observed however when animals were exposed to pheromone stimulation (male mouse urine) to induce preovulatory LH surges. In proestrous animals, mean LH levels at 18.30–19.00 h were reduced by about 66% in NPY-KO versus WT mice (4.33 ± 1.12 ng/ml in the WT mice vs. 1.47 ± 0.42 ng/ml in the NPY-KO mice, p = 0.028). Despite diminishment of LH surges in NPY-KO mice, corpora lutea were equally abundant in the ovaries of NPY-KO and WT mice. In an additional experiment, a surge-inducing regimen of estradiol-17-β (E2) and estradiol benzoate (E2B) was administered to OVX animals. The LH surges in the NPY-KO animals treated in this manner were again diminished by approximately 50% compared to corresponding values in WT animals (WT mice 7.33 ± 0.97 ng/ml, NPY-KO mice 3.58 ± 0.74 ng/ml; p = 0.0063). To assess the contribution of altered pituitary responsiveness to the diminishment of LH surges, LH responses to a GnRH challenge (200 ng/kg subcutaneously) were determined; NPY-KO animals exhibited LH responses that were significantly reduced compared to values in WT mice (WT mice 4.88 ± 0.56 ng/ml, NPY-KO mice 3.00 ± 0.41 ng/ml; p = 0.013). Taken together, these observations do not support the idea that NPY plays a major role in the regulation of basal gonadotropin secretion or in mediating negative feedback actions of gonadal hormones. They demonstrate however that preovulatory NPY release is required for normal amplification of the LH surge that occurs on proestrus. Involvement of NPY in the generation of normal LH surges is partially mediated by the ability of the peptide to prime the anterior pituitary gland to GnRH stimulation.

1.
Sutton SW, Toyama TT, Otto S, Plotsky PM: Evidence that neuropeptide Y (NPY) released into the hypophysial-portal circulation participates in priming gonadotropes to the effects of gonadotropin releasing hormone (GnRH). Endocrinology 1988;123:1208–1210.
2.
Sahu A, Jacobson W, Crowley WR, Kalra SP: Dynamic changes in neuropeptide Y concentrations in the median eminence in association with preovulatory luteinizing hormone release in the rat. J Neuroendocrinol 1989;1:83–87.
3.
Bauer-Dantoin AC, McDonald JK, Levine JE: Neuropeptide Y potentiates luteinizing hormone (LH)-releasing hormone-stimulated LH surges in pentobarbital-blocked proestrous rats. Endocrinology 1991;129:402–408.
4.
Bauer-Dantoin AC, McDonald JK, Levine JE: Neuropeptide Y potentiates luteinizing hormone (LH)-releasing hormone-induced LH secretion only under conditions leading to preovulatory LH surges. Endocrinology 1992;131:2946–2952.
5.
Bauer-Dantoin AC, Knox KL, Schwartz NB, Levine JE: Estrous cycle stage-dependent effects of neuropeptide-Y on luteinizing hormone (LH)-releasing hormone-stimulated LH and follicle-stimulating hormone secretion from anterior pituitary fragments in vitro. Endocrinology 1993;133:2413–2417.
6.
Leupen SM, Besecke LM, Levine JE: Neuropeptide Y Y1-receptor stimulation is required for physiological amplification of preovulatory luteinizing hormone surges. Endocrinology 1997;138:2735–2739.
7.
Leupen SM, Levine JE: Role of protein kinase C in facilitation of luteinizing hormone (LH)-releasing hormone-induced LH surges by neuropeptide Y. Endocrinology 1999;140:3682–3687.
8.
Kalra SP, Fuentes M, Fournier A, Parker SL, Crowley WR: Involvement of the Y-1 receptor subtype in the regulation of luteinizing hormone secretion by neuropeptide Y in rats. Endocrinology 1992;130:3323–3330.
9.
Li S, Hong M, Fournier A, St-Pierre S, Pelletier G: Role of neuropeptide Y in the regulation of gonadotropin-releasing hormone gene expression in the rat preoptic area. Brain Res Mol Brain Res 1994;26:69–73.
10.
Raposinho PD, Broqua P, Pierroz DD, Hayward A, Dumont Y, Quirion R, Junien JL, Aubert ML: Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype. Endocrinology 1999;140:4046–4055.
11.
Barker-Gibb ML, Scott CJ, Boublik JH, Clarke IJ: The role of neuropeptide Y (NPY) in the control of LH secretion in the ewe with respect to season. NPY receptor subtype and the site of action in the hypothalamus. J Endocrinol 1995;147:565–579.
12.
Pierroz DD, Gruaz NM, d’Alièves V, Aubert ML: Chronic administration of neuropeptide Y into the lateral ventricle starting at 30 days of life delays sexual maturation in the female rat. Neuroendocrinology 1995;61:293–300.
13.
Wehrenberg WB, Corder R, Gaillard RC: A physiological role for neuropeptide Y in regulating the estrogen/progesterone induced luteinizing hormone surge in ovariectomized rats. Neuroendocrinology 1989;49:680–682.
14.
Woller MJ, McDonald JK, Reboussin DM, Terasawa E: Neuropeptide Y is a neuromodulator of pulsatile luteinizing hormone-releasing hormone release in the gonadectomized rhesus monkey. Endocrinology 1992;130:2333–2342.
15.
Raposinho PD, Broqua P, Hayward A, Akinsanya K, Galyean R, Schteingart C, Junien J, Aubert ML: Stimulation of the gonadotropic axis by the neuropeptide Y receptor Y1 antagonist/Y4 agonist 1229U91 in the male rat. Neuroendocrinology 2000;71:2–7.
16.
Erickson JC, Clegg KE, Palmiter RD: Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y (see comments). Nature 1996;381:415–421.
17.
Erickson JC, Hollopeter G, Palmiter RD: Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y (see comments). Science 1996;274:1704–1707.
18.
Erickson JC, Ahima RS, Hollopeter G, Flier JS, Palmiter RD: Endocrine function of neuropeptide Y knockout mice. Regul Pept 1997;70:199–202.
19.
Chappell PE, Schneider JS, Kim P, Xu M, Lydon JP, O’Malley BW, Levine JE: Absence of gonadotropin surges and gonadotropin-releasing hormone self-priming in ovariectomized (OVX), estrogen (E2)-treated, progesterone receptor knockout (PRKO) mice. Endocrinology 1999;140:3653–3658.
20.
Bingel AS, Schwartz NB: Pituitary LH content and reproductive tract changes during the mouse oestrous cycle. J Reprod Fertil 1969;19:215–222.
21.
Bronson FH, Vom Saal FS: Control of the preovulatory release of luteinizing hormone by steroids in the mouse. Endocrinology 1979;104:1247–1255.
22.
Woller MJ, Terasawa E: Changes in pulsatile release of neuropeptide-Y and luteinizing hormone (LH)-releasing hormone during the progesterone-induced LH surge in rhesus monkeys. Endocrinology 1994;135:1679–1686.
23.
Terasawa E: Control of luteinizing hormone-releasing hormone pulse generation in nonhuman primates. Cell Mol Neurobiol 1995;15:141–164.
24.
Sutton SW, Mitsugi N, Plotsky PM, Sarkar DK: Neuropeptide Y (NPY): A possible role in the initiation of puberty. Endocrinology 1988;123:2152–2154.
25.
McDonald JK, Tigges J, Tigges M, Reich C: Developmental study of neuropeptide Y-like immunoreactivity in the neurohypophysis and intermediate lobe of the rhesus monkey (Macaca mulatta). Cell Tissue Res 1988;254:499–509.
26.
Minami S, Frautschy SA, Plotsky PM, Sutton SW, Sarkar DK: Facilitatory role of neuropeptide Y on the onset of puberty: Effect of immunoneutralization of neuropeptide Y on the release of luteinizing hormone and luteinizing-hormone-releasing hormone. Neuroendocrinology 1990;52:112–115.
27.
Woller MJ, Terasawa E: Estradiol enhances the action of neuropeptide Y on in vivo luteinizing hormone-releasing hormone release in the ovariectomized rhesus monkey. Neuroendocrinology 1992;56:921–925.
28.
Urban JH, Das I, Levine JE: Steroid modulation of neuropeptide Y-induced luteinizing hormone releasing hormone release from median eminence fragments from male rats. Neuroendocrinology 1996;63:112–119.
29.
Bauer-Dantoin AC, Urban JH, Levine JE: Neuropeptide Y gene expression in the arcuate nucleus is increased during preovulatory luteinizing hormone surges. Endocrinology 1992;131:2953–2958.
30.
Watanobe H, Takebe K: Evidence that neuropeptide Y secretion in the median eminence increases prior to the luteinizing hormone surge in ovariectomized steroid-primed rats: Estimation by push-pull perfusion. Neurosci Lett 1992;146:57–59.
31.
Kaynard AH, Spies HG: Immunoneutralization of neuropeptide Y suppresses luteinizing hormone secretion in rabbits. Endocrinology 1991;128:2769–2775.
32.
Barraclough CA, Turgeon JL, Cramer OM: Neural correlates of adenohypophyseal LH release in rats; in Stumpf WE, Grant LD (eds): Anatomical Neuroendocrinology. Basel, Karger, 1975, p 200.
33.
Kaynard AH, Pau KY, Hess DL, Spies HG: Third-ventricular infusion of neuropeptide Y suppresses luteinizing hormone secretion in ovariectomized rhesus macaques. Endocrinology 1990;127:2437–2444.
34.
Pierroz DD, Catzeflis C, Aebi AC, Rivier JE, Aubert ML: Chronic administration of neuropeptide Y into the lateral ventricle inhibits both the pituitary-testicular axis and growth hormone and insulin-like growth factor I secretion in intact adult male rats. Endocrinology 1996;137:3–12.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.